Part I. Design of a novel class of reversible non-covalent small molecule inhibitors for human Granzyme B (hGrB) Part II. Curcumin and mimics as proteasome inhibitors Part III. Design of novel coactivator binding inhibitors (CBIs) for the estrogen receptor α : break the 1µM barrier

Computer-Assisted Drug Discovery Part I: Design, Development, Validation and Application of FRESH, a Novel In-Silico High-throughput Screening Program Part II: Monocarbonyl Curcumin Analogues: Heterocyclic Pleiotropic Kinase Inhibitors that Mediate Anticancer Properties Part III: Development of 2nd Generation NAMFIS Software Program by Java

Computational Studies of Ligand Protein Interactions Part I: TheT-Taxol Conformation Part II: Elucidating Interdependent BindingSites on Tubulin

Validation of Receptor-Based Drug Design and Applications in the Study of IKKs, Truncated Taxane and LRH-1

Screening, hit expansion and mechanistic studies for natural product analogs derived from traditional herbal medicine: curcumin and triptolide.

Use of Receptor-Based Drug Design and Applications in the Study of finding antagonists for MD-2/TLR4, GLP and CXCR4

Paclitaxel and Cyclostreptin in theTubulin Binding Site